Years of losses, thin profit margins leave 160 Health feeling down
After two earlier failures, the online healthcare platform’s IPO has been approved by the Hong Kong Stock Exchange Key Takeaways: 160 Health has been approved to list in Hong Kong,…
Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
Anew Health taps investor ‘Qi’ with Nasdaq listing plan
The Hong Kong-based provider of pain relief services using traditional Chinese principles aims to raise about $7.2 million through its U.S. listing, valuing it at up to $200 million Key…
Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
Will new investor Goldstream bring its Midas touch to Saint Bella?
The investment company disclosed its purchase of 0.3% of the maternity and baby care company’s stock on the open market Key Takeaways: Goldstream Investment acquired 1.83 million Saint Bella shares,…
Ab&B fortifies for battle over China’s vaccine market
With proceeds from a Hong Kong IPO, the loss-making biotech is bidding for a piece of China’s fiercely competitive market for flu and human rabies vaccines Key Takeaways: The company’s…
Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
